What is Acrivon Therapeutics, Inc. Common Stock?
, a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 49.35M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 917,967 shares $37k | 0 |
| 3-6months | 84,718 shares $9k | 0 |
| 6-9months | 0 | 0 |
| 9-12months | 0 | 367,832 shares $114k |